Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepagene (PowderJect).

Taff Jones1

  • 1Intellivax International Inc, Ville St-laurent, Quebec, Canada. tjones@intellivax.com

Current Opinion in Investigational Drugs (London, England : 2000)
|August 21, 2002
PubMed
Summary
This summary is machine-generated.

Hepagene, a recombinant polyvalent vaccine, was developed for hepatitis B virus infections. Evaluation neared completion in 2001, with potential launch expected soon after.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of nasal IgA in children vaccinated with live attenuated influenza vaccine.

Vaccine·2012
Same author

Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials.

PloS one·2010
Same author

Vacc-4x, a therapeutic vaccine comprised of four engineered peptides for the potential treatment of HIV infection.

Current opinion in investigational drugs (London, England : 2000)·2010
Same author

GSK's novel split-virus adjuvanted vaccines for the prevention of the H5N1 strain of avian influenza infection.

Current opinion in molecular therapeutics·2009
Same author

IC-51, an injectable vaccine for the prevention of Japanese encephalitis virus infection.

Current opinion in molecular therapeutics·2009
Same author

IMVAMUNE, an attenuated modified vaccinia Ankara virus vaccine for smallpox infection.

Current opinion in molecular therapeutics·2008

Area of Science:

  • * Vaccinology and virology, focusing on recombinant vaccine development.
  • * Hepatitis B virus (HBV) infection and prevention strategies.

Background:

  • * Hepatitis B virus (HBV) poses a significant global health challenge.
  • * Development of effective vaccines is crucial for controlling HBV transmission.

Purpose of the Study:

  • * To summarize the development and evaluation of Hepagene, a novel recombinant polyvalent vaccine for HBV.
  • * To highlight the vaccine's antigenicity and potential market entry.

Main Methods:

  • * Development of a recombinant polyvalent vaccine (Hepagene) utilizing S, pre-S1, and pre-S2 hepatitis B epitopes.
  • * Glycosylation of surface markers to enhance resemblance to the live virus.
  • * Evaluation of Hepagene, including assessment with needle-less injection technology.

Related Experiment Videos

Main Results:

  • * Hepagene is a polyvalent vaccine designed to target hepatitis B virus infections.
  • * Product evaluation was nearing completion by July 2001.
  • * A potential launch was anticipated in the months following July 2001.

Conclusions:

  • * Hepagene represents a novel approach to hepatitis B vaccination.
  • * The vaccine showed promise for market entry, with potential for therapeutic applications.
  • * Financial projections indicated significant market potential, with peak sales estimated at US $600 million.